With the commercial success of two well-known brands, pharmaceutical companies have an intense interest in additional therapeutics for the treatment of both obesity and type 2 diabetes. Ralph F. Hirschmann Prof. Samuel Gellman worked with postdoc Kyle Brown and graduate student Rylie Morris to develop a synthetic peptide that uses a more simplified design to target the same mechanisms of the drugs currently on the market.
To disclose your invention visit:
warf.org/disclose
To license a WARF technology visit:
warf.org/commercialize
28 ноя 2023
